These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22104158)

  • 1. Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer.
    Jacobs VR; Mayer SC; Paessens BJ; Bernard R; Harbeck N; Kiechle M; Ihbe-Heffinger A
    Onkologie; 2011; 34(11):614-8. PubMed ID: 22104158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
    Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
    Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Revenue and losses with vertebral augmentation under the G-DRG system 2012 - a comparison of supply costs in the context of vertebroplasty and kyphoplasty].
    Krüger A; Wollny M; Oberkircher L; Bornemann R; Pflugmacher R
    Z Orthop Unfall; 2012 Oct; 150(5):539-46. PubMed ID: 23076753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Revenue Situation in Interventional Radiology Based on the Example of Peripheral Artery Disease in the Case of a DRG Payment System and Various Internal Treatment Charges.
    Vogt FM; Hunold P; Haegele J; Stahlberg E; Barkhausen J; Goltz JP
    Rofo; 2018 Apr; 190(4):348-358. PubMed ID: 29495050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
    Stäbler W; Wagner B
    Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer.
    Braun M; Jacobs VR; Wagenpfeil S; Sattler D; Harbeck N; Nitz U; Bernard R; Kuhn W; Ihbe-Heffinger A
    Onkologie; 2009 Sep; 32(8-9):473-81. PubMed ID: 19736510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
    Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
    Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
    J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Economic burden of Clostridium difficile enterocolitis in German hospitals based on routine DRG data].
    Grube RF; Heinlein W; Scheffer H; Rathmayer M; Schepp W; Lohse AW; Stallmach A; Wilke MH; Lerch MM;
    Z Gastroenterol; 2015 May; 53(5):391-7. PubMed ID: 25965986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy for colon cancer--analysis of treatment costs from the perspective of statutory sickness funds.
    Görner M; Riemer-Hommel P
    Z Gastroenterol; 2008 Jul; 46(7):681-8. PubMed ID: 18618379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of direct medical costs of hospitalization for febrile neutropenia.
    Lathia N; Mittmann N; DeAngelis C; Knowles S; Cheung M; Piliotis E; Shear N; Walker S
    Cancer; 2010 Feb; 116(3):742-8. PubMed ID: 20029970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
    Ramsey SD; Liu Z; Boer R; Sullivan SD; Malin J; Doan QV; Dubois RW; Lyman GH
    Value Health; 2009; 12(2):217-25. PubMed ID: 18673353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Underfinancing of 90.3% for implant costs of prostheses and expanders in DRG revenues for uni- and bilateral mastectomy with immediate breast reconstruction.
    Jacobs VR; Rasche L; Harbeck N; Warm M; Mallmann P
    Onkologie; 2010; 33(11):584-8. PubMed ID: 20975304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant anthracyclines and taxanes: quantifying the costs of therapeutic advances in breast cancer.
    Morris PG; Bach PB
    Onkologie; 2009 Sep; 32(8-9):464-6. PubMed ID: 19745589
    [No Abstract]   [Full Text] [Related]  

  • 16. [Primary hip- and knee arthroplasty--comparison of the actual costs with the Australian diagnosis related groups (DRG)-].
    Schürmann N; Müller RT
    Z Orthop Ihre Grenzgeb; 2002; 140(6):589-94. PubMed ID: 12476379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An economic analysis of aseptic revision hip arthroplasty: calculation of partial hospital costs in relation to reimbursement.
    Assmann G; Kasch R; Hofer A; Schulz AP; Kayser R; Lahm A; Merk H; Flessa S
    Arch Orthop Trauma Surg; 2014 Mar; 134(3):413-20. PubMed ID: 24477287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
    Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
    Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
    Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost comparison of capecitabine in patients with breast cancer.
    Rugo HS; Kohles J; Schulman KL
    Am J Clin Oncol; 2010 Dec; 33(6):550-6. PubMed ID: 20051811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.